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Background: Lafora disease is an autosomal recessive form of progressive myoclonic epilepsy caused by defects in
the EPM2A and EPM2B genes. Primary symptoms of the pathology include seizures, ataxia, myoclonus, and
progressive development of severe dementia. Lafora disease can be caused by defects in the EPM2A gene, which
encodes the laforin protein phosphatase, or in the NHLRC1 gene (also called EPM2B) codifying the malin E3
ubiquitin ligase. Studies on cellular models showed that laforin and malin interact and operate as a functional
complex apparently regulating cellular functions such as glycogen metabolism, cellular stress response, and the
proteolytic processes. However, the pathogenesis and the molecular mechanism of the disease, which imply either
laforin or malin are poorly understood. Thus, the aim of our study is to elucidate the molecular mechanism of the
pathology by characterizing cerebral cortex neurodegeneration in the well accepted murine model of Lafora
disease EPM2A-/- mouse.
Results: In this article, we want to asses the primary cause of the neurodegeneration in Lafora disease by studying
GABAergic neurons in the cerebral cortex. We showed that the majority of Lafora bodies are specifically located in
GABAergic neurons of the cerebral cortex of 3 months-old EPM2A-/- mice. Moreover, GABAergic neurons in the
cerebral cortex of younger mice (1 month-old) are decreased in number and present altered neurotrophins and
p75NTR signalling.
Conclusions: Here, we concluded that there is impairment in GABAergic neurons neurodevelopment in the
cerebral cortex, which occurs prior to the formation of Lafora bodies in the cytoplasm. The dysregulation of
cerebral cortex development may contribute to Lafora disease pathogenesis.
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Lafora disease (OMIM 254780) is an autosomal recessive
form of epilepsy with onset in late childhood or adoles-
cence [1-3]. Primary symptoms include seizures, ataxia,
myoclonus, and the progressive development of severe
dementia. Most affected individuals die by 25 years of
age. Currently, there is no long-term treatment available.
Clinically, Lafora disease is characterized by the presence
of inclusion bodies, called Lafora bodies (LBs), which are
present in several organs, including brain, heart, liver,
muscle, and skin. LBs contain around 6% of protein and* Correspondence: carlos.spuch@gmail.com
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unless otherwise stated.90% of a poorly branched form of glycogen, which resem-
bles amylopectin [4], suggesting that in Lafora disease, en-
zymes involved in glycogen metabolism are dysregulated.
The great majority of mutations causing Lafora disease
have been identified in two genes: EPM2A (encoding
laforin) a member of the dual-specificity protein phosphat-
ase family [5,6], and NHLRC1 (encoding malin) a protein
with an NH2-terminal RING finger domain, characteristic
of an important group of E3-ubiquitin ligases [7,8]. There
is also evidence for the existence of a third locus [9], which
was recently mapped in position 4q21.21, where is located
the PRDM8, a gene of unknown function [10]. Patients
carrying homozygous mutations in laforin or malin are
phenotypically indistinguishable, suggesting that both pro-
teins contribute to the same physiological pathway. LBs
are localized in cell cytoplasm in several organs of affected
patients. Although LBs are the hallmark of the disease, ital Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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or are a simple consequence of this condition in the brain.
LBs presence appears to be restricted to neurons, however
in 2011 Valles-Ortega et al. described the accumulation of
polyglucosan in the astrocytes of malin-KO mice [11].
Polyglucosan inclusions gradually replace the cytoplasms
in a large number of dendrites, likely underlying onset and
progression of this disease. The LBs are also marked by
anti-ubiquitin antibodies, suggesting the accumulation of
unmetabolized proteins in the bodies [12]. Therefore,
Lafora disease may be a disorder of both carbohydrate
metabolism and protein clearance [13].
Laforin is a member of the atypical dual specificity pro-
tein phosphatase family [5], which additionally contains a
functional CBM20 carbohydrate-binding module. Two
different, not mutually exclusive, roles have been sug-
gested for laforin. First, laforin could act as a glycogen
phosphatase, removing phosphatases from glycogen and
preventing the soluble glycogen molecules from becoming
insoluble polyglucosan [14-16]. On the other end, laforin
interacts with the E3 ubiquitin ligase, malin, driving spe-
cific substrates related to glycogen metabolism in proxim-
ity of malin to be polyubiquitinated and degraded by the
proteosome complex [17,18]. Experiments by Roach pro-
posed that laforin is a physiological glycogen phosphatase
whose impairment leads to the structural abnormalities in
glycogen and to LB formation [14,16].
Several transgenic mouse models have been developed
for Lafora disease, either by disruptiing EPM2A gene (null
mice) [12] or by over-expressing inactivated laforin [19] in
all tissues. A malin knock out mouse was also developed
by disruption of the NHLRC1 gene [16,20]. All these
transgenic models mimic the human disease, since mice
LBs are accumulated in cell cytosol and they develop epi-
lepsy, however they differ from affected patients in terms
of life span, which is not shortened in the animals.
The development of a Lafora like phenotype in laforin
knockout animals supports the hypothesis that laforin
dephosphorylates glycogen in vivo [14]. Increased phos-
phorylation is associated with disturbances in glycogen
structure that are consistent with LB formation [15]. LB
accumulation was believed to coincide with increased
neuronal non-apoptotic cell death, development of sei-
zures in Lafora patients [12] and ultimately, for patient’s
death [4]. Brain biopsies confirmed the accumulation of
starch-like compound in neuron, overtaking dendrites,
as a possible cause of disease and neurodegeneration.
This hypothesis was corroborated by Minsassian [21]
et al., which showed for the first time, that the removal
of a protein targeting to glycogen (PTG) in an animal
model of Lafora disease reduced LB formation and
eliminates neuronal loss and the myoclonic epilepsy.
Despite the fact that the genetic defect in Lafora’s pa-
tients is present since birth, any molecular explanationfor the disease must take into account the gradual na-
ture of pathology onset, whose symptoms usually appear
in teenage years [22]. A well accepted hypothesis states
that symptoms of the disease are a consequence of LB
accumulation, which in neurons leads to cell death and
the associated epilepsy, myoclonus and ataxia. Neverthe-
less, considering that not all neurons undergoing cell
death in the laforin ko mouse present visible LB, we
propose that LB formation could be the final result of
multiple aberrant steps in glycogen synthesis, and that
earlier non-visible products are responsible for neuronal
apoptosis. Based on this hypothesis, we provide evidence
that prior to the development of the first LB there is a
specific damage in neurodevelopment of GABAergic
neurons in the cerebral cortex.
Results
Lafora bodies are specifically located in GABAergic
cortical neurons at early age
We detected the presence of LBs in neurons of EPM2A-/-
mice at 3 and 13 months-old by immunostaining of
neuronal marker βIII-Tubulin, Periodic acid–Schiff
(PAS) and KM279 polyglucosan immumoreactive anti-
body (Additional file 1: Figure S1). LBs are easy to
localize by microscope, since light is refracted through
the body. We combined βIII-Tubulin and PAS staining
to detect LBs specifically located in neurons. It LBs,
commonly distinguished by size and location, are com-
partmentalized to perikaryon and dendrites and not to
axons. The bigger LBs are located in the perikaryal and
the granular LBs are placed in the neuronal processes,
mostly represented by dendrites [19,21].
To characterize the causes of neurodegeneration we
evaluated PAS positives ground-glass inclusions, as well
as LBs, in all brain regions of EPM2A-/- mice at the
ages of 5 and 15 days and 1, 3, 5, 13 and 18 months. Al-
though the LBs and ground-glass inclusions appear in all
brain regions, the highest density was placed in cerebral
cortex and hippocampus (Additional file 2: Figure S2),
with lower amounts in the basal forebrain and random
distribution throughout the rest of the brain. Ultra-
structural analysis of the neuropile in the brain of
EPM2A-/- mice revealed unequivocal features of som-
atic degeneration in cerebellar Purkinje cells (isolated
or in full rows), hippocampal pyramidal and granular
cells, and cerebral cortical pyramidal cells at early age
(2 months-old mice) [12]. However, overtime evalu-
ation of PAS positive inclusions that we performed re-
vealed that the first LB in the cytoplasm appears 3
months old mice, while the PAS-positive ground-glass
inclusions are present as early as at 1 month of age.
Therefore we estimated that the time window for the ini-
ciation of the neurodegenerative processes could be fixed
between 15 days and 1 month of age. For this reason, we
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EPM2A-/- in this range of time.
The first signal of the possible role of a dysfunction in
cerebral cortex in Lafora disease came form the evidence
that in 3 months-old EPM2A-/- all the LBs were specifically
located in GABAergic neurons (GABAergic cells: so
called because their neurotransmitter is gamma-
aminobutyric acid or GABA) of the cerebral cortex
(Figure 1), while LBs were located in all types of neu-
rons in mice over 3 months old.
We also carried out immnostaining of GABAergic neu-
rons with GAD67 marker in cerebral cortex, showing that
all the LBs are placed in the GABAergic cortical neurons
before 3 months (Figure 1A, LBs marked with arrows).
GAD67 was previously used to identify GABAergic cortical
neurons [23]. This result was confirmed with double stain-
ing of GAD67 positive neurons with either PAS (Figure 1B)
or polyglucosan marker KM279 antibody (Figure 1C, LBs
in red, GABAergic neurons in green).
The population of GABAergic cortical neurons is reduced
in Laforin-deficient mice
We performed a comparative study of GABAergic neu-
rons density in the cerebral cortex between EPM2A-/-
and wild type mice at the age of 15 days-old and 1
month-old. The density of GAD67 positive neurons in
the cortical layers was estimated by dividing the number
of GAD67 neurons by the surface area in the cortical layer.
We could not find any differences between groups (wild
type vs. EPM2A-/-) until postnatal day 15 (P15). Following
the analysis, we found that there was a significant reduc-
tion of (54.70%) in the number of GAD67 neurons in
EPM2A-/- compared to wild-type mice (Figure 2A) at one
month, coinciding with the appearance of the first LB in
the cortical area of EPM2A-/- brain. We also found that at
P30 GAD67 positive cell density increases in wild type
mice compared to levels detected at P15, while it is main-
tained in EPM2A-/- mice, highlighting an impairment of
GABAergic neurons development in the knockout mouse
(Figure 2A). The comparative study was repeated by im-
munofluorescence, to quantify GAD67 fluorescence in
confocal microscopy images using the Leica AMD mor-
phometric software. We measured GAD67 intensity in
random slides of cortical areas samples from 1 month-old
wild-type and EPM2A-/- mice (Figure 2B) and find that
GAD67 intensity was decreased of 61.20% (p < 0.05).
To further confirm our results, we measured GAD67
levels in brain cerebral cortex lysates from wild-type and
EPM2A-/-, by western blot. Compatibly with previous
data, we detected a significant reduction of GAD67 in
EPM2A-/- mice at P30 (Figure 2C), since the neuronal
population decrease at 47.60%. To exclude that the ab-
sence of laforin could interfere with GAD67 production,
we repeated the western blot analysis using the Anti-GABA transporter-3 antibody (Millipore), obtaining re-
sults comparable to the previously described experiment
(Figure 2C).
Loss of synapses in the cerebral cortex of
Laforin-deficient mice
We analyzed the levels of synaptic protein in cerebral cor-
tex on EPM2A-/- mice compared to wild-type. We per-
formed western blot experiments using cortex cellular
lysates from 1 month-old EPM2A-/- and wild-type mice.
One month-old EPM2A-/- mice showed a dramatic de-
crease of immunoreactive levels of two synaptic proteins
(synaptophysin and synaptotagmin) (Figure 3A). These re-
sults were confirmed through immunofluorescence and
confocal microscope analysis; finding synaptophysin reduc-
tion in the cerebral cortex of EPM2A-/-mice (Figure 3B).
To determine whether synaptic loss is due to LBs or to a
lack of laforin, we measured both synaptic proteins (synap-
tophysin and synaptotagmin) in brain cerebral cortex at
P5, P15 and P30 EPM2A-/- mice, finding that the levels of
synaptic proteins were reduced at very early ages, starting
at P5 EPM2A-/- mice (Figure 3C).
Increase of lysosomal activity and actin disarrangement in
cortical neurons of Laforin-deficient mice
We measured lysosomal activity with confocal microscopy
and western blot experiments in cerebral cortex of
EPM2A-/- at 1 and 9 months of age, compared with
wild-type mice. Confocal microscopy, revealed a strong in-
crease in LAMP2 intensity at 9 months (p < 0.001), how-
ever, we also found a slight increase of florescence signal
at 1 month-old (p < 0.01) (Figure 4A). Western blot ana-
lysis confirmed an increased LAMP2 expression in cere-
bral cortex lysates from EPM2A-/- mice (Figure 4B).
To investigate whether the presence of LBs are impli-
cated in the cytoskeletal organization, we stained cere-
bral cortex of EPM2A-/- at 1 and 9 months-old with the
filamentous actin indicator rhodamine-phalloidin. The
confocal images revealed a significant disarrangement of
F-actin in brains of laforin-deficient mice but only at the
age of 9 months. White arrows indicate cytoskeleton dis-
arrangement in neurons cytoplasm [Figure 4C].
Increase of caspase-3 activity in cortical neurons of
Laforin-deficient mice
To study whether the lack of laforin induced a specific
damage in GABAergic neurons we performed immuno-
staining and western blot for active-caspase-3 to detect
apoptotic neurons in P5, P15 and P30 EPM2A-/- mice.
We found an increase of active-caspase-3 in the cerebral
cortex of 1 month-old EPM2A-/- mice (Figure 5), however
we could not detect TUNEL-positive neurons (data not
show). In some apoptotic pathways caspase-9 is upstream
to caspase-3, thus, we checked caspase-9 activation in the
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Figure 1 LBs are specifically localized in GABAergic cortical neurons. A) Broad image of the specific localization of LBs are only in
GABAergic cortical neurons in paraffin sections of temporal cortex of EPM2A-/- mice (3 months-old) revealed with DAB. The cortical neuronal
marker used in the immunostaining is the GAD67. B) Magnification of the picture 3A (left) of LBs located in the cytoplasm and combination with
PAS staining (right). C) Immunofluorescence of GAD67 (green), polyglucosan antibody (red) and DAPI staining (blue) in wild type (left) and
EPM2A-/- mice (right). These results showed that the specific localization of LBs exclusively in the GABAergic neurons at early ages gives us a new
perspective about the sensible damage induced in these neurons due to laforin deficiency.
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ingly by co-staining neurons with Glutamine synthetase
Clone Gs-6 marker (red) and active-caspase-3 (green), we
found that active-caspase-3 appeared only in the gluta-
matergic neurons of the cerebral cortex (Figure 5D).Laforin deficiency induces nuclear translocation of p53 in
the cerebral cortex
The subcellular localization of p53 seems to play an
important role in the activity of the protein. Both, im-
port into the nucleus and export to the cytoplasm,
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Figure 2 Decrease of GABAergic neurons density in laforin-deficient mice. We measured by different techniques the decrease of GABAergic
cortical neurons in EPM2A-/- mice (1 month-old) (*P < 0.05). A) Immunohistochemistry performed in paraffin section of temporal cortex revealed with
DAB, showing a strong reduction of GABAergic cortical neurons. Cell counting of GABAergic cortical neurons in 15 days-old and 1 month-old EPM2A-/-
mice (n = 3) shows a significant reduction of 54.70% in the number of GAD67 neurons in EPM2A-/- compared with wild-type, which suggest the
importance of the temporary window between 15 days and 1 month of age. B) Immunofluorescence and confocal study (n = 3) corroborating the
same results. C) Cerebral cortex lysates measured by western blot (n = 5). This gel shows a clear GAD67 reduction in the cerebral cortex of 1 month old
laforin-deficient mice.
Ortolano et al. Molecular Brain 2014, 7:7 Page 5 of 17
http://www.molecularbrain.com/content/7/1/7appear to be mediated by specific pathways that are
associated with either the stabilization of the active
protein or its inactivation by degradation. Nuclear
localization of p53 was shown to be mediated bynuclear localization signals. We measured the content
of p53 in the nuclear and cytoplasmic fractions of cor-
tical neurons from P15 and P30 mice by western blot.
p53 protein was mainly localized in the nuclear
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Figure 3 Synaptic damage in the cerebral cortex of EPM2A-/- mice (1 month-old) measured by different techniques. A) Representative
western blot of quantification of two synaptic proteins (synaptophysin and synaptotagmin) in cerebral cortex lysates (n = 5). Comparable
amounts of samples are loaded. This result demonstrated clearly the reduction synaptic proteins in the cerebral cortex of laforin-deficiency
mice. B) Semi-quantification of synaptophysin measured by confocal microscopy in sections of cerebral cortex of EPM2A-/- mice (n = 3).
Moreover, this experiment also revealed the reduction of synaptic protein in these mice. C) Western blot quantification of two synaptic
proteins, synaptophysin and synaptotagmin, in cerebral cortex lysates of EPM2A-/- mice at different ages: 5, 15 and 30 days-old. These results
illustrates that the synaptic damage occur at very early ages. Results are mean ± SEM *p < 0.05, **p < 0.01 wild-type mice vs EPM2A -/- mice
(ANOVA followed by Student’s t test).
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Figure 4 Increase of lysosomal activity in the cerebral cortex of EPM2A-/- mice. A) Confocal images of LAMP2 (green) and quantification of
LAMP2 intensity in cerebral cortex of EPM2A-/-mice at 1 and 9 months of age (n = 5). Results are mean ± SEM ** p < 0.01 and *** p < 0.001 wild-type
mice vs EPM2A -/- mice (ANOVA followed by Student’s t test). This quantification showed the increase of lysosomal activity in the cerebral cortex at late
ages. B) Quantification of LAMP2 protein in cerebral cortex lsyates of EPM2A-/- mice (1 month-old, n = 5). Western blots represent the increase of the
LAMP2 protein in the cerebral cortex lysates. C) F-actin accumulation in cerebral cortex of EPM2A-/- mice. Sections of cerebral cortex were stained with
rhodamine-phalloidin. F-actin was detected in small clusters in the cell body of neurons in the cerebral cortex only in older laforin-deficient mice. The
clusters of disarrangement of F-actin are pointed with white arrows in the representative picture.
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http://www.molecularbrain.com/content/7/1/7fractions (Figure 6A), at both stages, while little signal
was detected in the cytoplasmic fraction. These pre-
liminary results suggest the implication of laforin inthe regulation of p53 subcellular localization, although
this hypothesis has to be confirmed through further
experiments.
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Figure 5 Increase of caspase-3 activity in cortical neurons of EPM2A-/- mice. A) Confocal images of cerebral cortex sections of EPM2A-/-
mice with active-caspase-3 (red) and GAD67 (green). B) Magnification of the microphotography in panel A. These representative images
revealed the activation of caspase-3 in non-GABAergic neurons. The GABAergic neurons contacts mainly with glutamatergic neurons and
these neurons seem to activate the caspase-3 in laforin-deficient mice. C) Representative western blot of active-caspase-3 and
active-caspase-9 quantification in the lysates of cerebral cortex in EPM2A-/- mice (1 month-old). D) Confocal images of cerebral cortex
sections of EPM2A-/- mice with active-caspase-3 (green) and glutamatergic neuronal marker Glutamine synthetase Clone Gs-6 (red).
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cerebral cortex of Laforin-deficient mice
Altered NGF and BDNF metabolism could be induced or
exasperated by neurodegeneration in the brain of patients
with Lafora disease. To characterize NGF and BDNF ex-
pression in cerebral cortex from EPM2A-/- mice, we carriedout western blot analysis of these two proteins and the
p75NTR, a receptor implicated in the apoptosis of neurons.
For these experiments we used cerebral cortex lysates from
15 days and 1 month-old mice. At both ages NGF and
BDNF levels decreased in EPM2A-/- mice, compared to
wild type controls, while p75NTR increased (Figure 7A).
1 month-old
p53
Cytoplasm
Actin
Nucleus
p53
NeuN
NeuN
Actin
15 days-old
p53
Cytoplasm
Actin
Nucleus
p53
NeuNNeuN
Actin
p53
Total level of p53
p53
Total level of p53
B
A
p75NTR
BDNF
15 days-old
Actin
NGF
1 month-old
p75NTR
Actin
NGF
BDNF
BDNF/Actin
0
20
40
60
80
100
120
*
p75NTR/Actin
0
40
80
120
160
200 *
NGF/Actin
0
20
40
60
80
100
120
*
BDNF/Actin
0
20
40
60
80
100
120
*
p75NTR/Actin
0
40
80
120
160
200
*
NGF/Actin
0
20
40
60
80
100
120
*
Figure 6 Altered levels of neurotrophins and subcellular distribution of p53 in cerebral cortex of EPM2A-/- mice. A) Subcellular
distribution of p53 in cerebral cortex of EPM2A-/- mice. In samples of cerebral cortex of EPM2A-/- and wild type mice (n = 5) at different ages (15 and 30
days-old), we measured the content of p53 in the nuclear and cytoplasmic fractions by western blot. This picture illustrates the accumulation of p53
protein in the nucleus fraction of the cerebral cortex in Laforin-deficiency mice compared to wild-type. There is no change in the content of p53 in lysate
of whole cerebral cortex at both ages. Results are mean ± SEM *p < 0.05, ** p < 0.01 wild-type mice vs EPM2A -/- mice (ANOVA followed by Student’s
t test). B) To characterize the NGF and BDNF expression in cerebral cortex from EPM2A-/- mice, we quantified the levels of the neurotrophins ligands NGF
and BDNF and the receptor implicated in the apoptosis of neurons, the p75NTR, in lysates of cerebral cortex by western blot analysis. This picture
illustrate the decrease of NGF and BDNF levels and the increase of p75NTR expression at both ages (n = 5). Comparable amounts of samples are loaded.
Representative western blot of NGF, BDNF and p75NTR and its quantification in 1 month old mice (*P < 0.05) and 15 days old mice (*P < 0.05).
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is also the evaluation of the presence or the accumula-
tion of p75NTR intracellular domain ICD-p75NTR
(20 KDa), which has recently been suggested to beinvolved in p75NTR signalling [24,25]. We described for
the first time the pathophysiological role of p75NTR in
Lafora disease and the possible increase in the ICD-
p75NTR levels.
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fraction, which was analyzed by western blotting. These representative blots revealed that the main changes between wild-type and EPM2A-/-
mice were noticed at 15 days-old and at 1 month-old. There was a significant decrease in the proteins implicated in neuroprotection and
neurorepair: TTR, ApoJ, BDNF, NGF, VEGF; and there was a significant increase in proteins implicated with neuropathological situations: β-Amyloid
1-40 and 1-42 and MMP9. Results are mean ± SEM *p < 0.05, **p < 0.01 wild-type mice vs EPM2A -/- mice (ANOVA followed by Student’s t test).
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(produced as described in the Methods section) to analyze
cerebral cortex samples from EPM2A-/- mice at P5, P15
and P30. The antibody revealed the presence of two bands
of 20-kDa and 25-kDa, respectively corresponding to the
ICD-p75 and the carboxyl terminal fragment (CTF)-
p75NTR [26,27], products of α- and γ-secretases activity.
Both fragments appeared to be increased in the cerebralcortex of P15 EPM2A-/-, as shown by densitometry ana-
lysis of the 20-kDa band respect to total p75NTR signal
revealed significant differences between the control and
Laforin deficient brains in the cerebral cortex (Figure 7A,
B and C).
The endogenous ICD-p75NTR was present in both
the cytoplasmic and nuclear fraction of the control sam-
ple. However, we did not detect nuclear translocation of
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(Figure 7D). To assess the specificity of the fraction-
ation procedure we checked the expression of NeuN, a
nuclear protein, and a cytoplasmic actin in cellular ly-
sates. Intramembrane cleavage events have been de-
tected in many cell types, not only for p75NTR. To test
whether the inhibition of nuclear translocation of ICD-
p75 in the cerebral cortex of Laforin-deficient mice is spe-
cific or presenilin-dependent, we assessed also the ICD
levels of Notch. We also confirmed that in EPM2A-/- mice
ICD-Notch did not translocate to the nucleus (Figure 7D).
This experiment upholds that in Lafora disease there is a
possible impairment of the proteolysis through presenilin-
dependent γ-secretase activity occuring at P15, before the
development of LBs.
The activity of intramembrane proteolysis determines
the release of soluble proteins in the milieu of cerebral
cortex. We analyzed the soluble proteins pattern in
EPM2A-/- mice cerebral cortex at P5, P15, and P30. Low
speed centrifugation of tissue extracts (see Methods sec-
tion) was used to isolate soluble fractions, which were ana-
lyzed by western blotting. The main alterations in
EPM2A-/- mice were noticed at P15 (15 days-old) and
P30 (1 month-old) (Figure 7E), revealing a significant de-
crease in proteins implicated in neuroprotection and neu-
rorepair, such as transthyrretin (TTR), Clusterin (ApoJ),
BDNF, NGF, VEGF) and a significant increase in proteins
implicated in neuropathological conditions, such as β-
Amyloid 1-40 and 1-42 and MMP9.
Discussion
Mice with mutated EPM2A gene develop many of the
characteristics of Lafora disease, since they show LBs in
liver, muscle and brain, as well as impaired behavioural re-
sponses, ataxia and ultimate appearance of spontaneous
myoclonic seizures [12]. Glycogen phosphate is already in-
creased in EPM2A-/- at 3 months of age, and continued to
rise over time [14]. LBs also appear around the third
month [15], while the epilepsy progression starts at around
9 months of age [12]. Grand mal tonic-clonic seizures,
which are almost invariably observed in Lafora disease pa-
tients, are clinically absent in 1 year-old mice [12], even in
presence of LBs, suggesting that additional factors, envir-
onmental or genetic, are contributing to the pathophysi-
ology of the disease. A possible interpretation of these
differences could be related to the diversity in the func-
tional organization of cortico-reticular-cortical pathways
between mice and humans.
In the present work, we confirmed the presence of LBs
in neurons of EPM2A-/- mice 3 and 13 months-old and
we also determined, for the first time, that polyglucosan
inclusions specifically affect GABAergic cortical neurons
at early stages. The specific localization of the inclusions
could be a key issue in interpreting the cerebral cortexdysfunction in Lafora disease. Pointing in this same direc-
tion, we also showed that the population of GABAergic
cortical neurons is reduced in Laforin-deficient mice,
which again underlie a possible specific role of GABAergic
neurons in the development of the disease. Interestingly,
autopsy of human patients showed that LBs are mainly
abundant in layers III and V of the cortex, and other ab-
normalities were also noted in the pyramidal cells of the
same layers [28]. The 15% of cortical neurons are local in-
hibitory interneurons, which are found in all cortical
layers. Using the synapse category as a guide, it is esti-
mated that 84% of all synaptic connections in the neocor-
tex are excitatory and 16% are inhibitory [29]. EEG studies
comparing Lafora disease with another progressive myo-
clonic epilepsy, Unverricht-Lundborg disease, have sug-
gested that the sensory and motor cortices in Lafora
disease are hyper-excitable in response to afferent stimuli
[30,31]. Through unknown mechanisms, the inhibitory
regulation of the cortex is impaired and seizures ensue. It
is known that the electrophysiological profiles of these
two diseases are quite distinct. When examining for motor
evoked potential modulation by afferent sensory stimuli,
there is early facilitation in Unverricht-Lundborg disease,
whereas Lafora disease has delayed and prolonged facilita-
tion [30].
At the same time we pretended to further characterize
the cause of neuronal degeneration in Lafora disease,
which could be due either to the presence of polyglucosan
inclusions, or to some metabolic defect most likely related
to laforin dysfunction. Neuronal cell death was described
by Ganesh et al, 2002 at all stages of EPM2A-/- mice be-
tween 2 to 12 month-old animals [12]. However, a rigorous
quantitative analysis for different age groups is necessary to
understand the spatial and temporal difference in inclu-
sions distribution to reveal the cause of degenerating
neurons. The defining characteristics of apoptosis, the
fragmentation of both cytoplasm and nucleus were not
found in the degenerating neurons. We evaluated neur-
onal cell death by TUNEL technique and we could not
find TUNEL positive cells, suggesting that cell death oc-
curs without the activation of apoptosis. It is worth to
point out that morphologically very similar features of
cell death have been previously described for neuronal
degeneration in Huntington disease, both in patients
and mouse models [32].
To characterize the causes of neurodegeneration we eval-
uated the number of PAS positives LBs and ground-glass in-
clusions, in all brain regions of EPM2A-/- mice. We found
that ground-glass inclusions localize preferentially in cere-
bral cortex and hippocampus (Additional file 2: Figure S2),
with lower amounts in the basal forebrain and random
distribution throughout the rest of the brain. Whether the
ground glass inclusions are precursors of LBs is still uncer-
tain, however it is possible that the formation of these
Ortolano et al. Molecular Brain 2014, 7:7 Page 12 of 17
http://www.molecularbrain.com/content/7/1/7inclusions could represent the first step of LBs formation
in the cytoplasm. Recently, Delgado-Escueta’s group de-
tected that cell death and LBs showed a progressive incre-
ment in size and number with age. They found that
ground-glass inclusions emerged at 2 weeks-old of age
and LBs appeared at 2 months-old of age [33]. Moreover,
there are ultraestructural evidences of neuronal somatic
degeneration in Purkinje cells, hippocampal pyramidal
and granular cells, and cerebral cortical pyramidal cells in
2 months old mice in spite of the appearance of the first
LBs at three months of age [12]. It is possible that the
absence of laforin could induce a specific damage in
GABAergic neurons previously to the appearance of first
the LBs, killing the affected neurons just between P15 and
P30. Alternatively, laforin could be the key factor in neur-
onal migration process, being involved in the maintenance
of the adequate environmental conditions in cerebral cor-
tex to induce GABAergic development. Indeed, it was
published that Lafora disease is associated with a reduc-
tion in cortical glucose metabolic rate and cerebral blood
flow and a lowered oxygen rate as determined by posi-
tron emission tomography [34]. Although we can not
exclude either of the two hypotheses, we suggest that a
correct balance between amounts of neurons of differ-
ent type is necessary for correct brain functionality and
that the proliferation of GABAergic neurons has to be
equilibrated with the generation of glutamatergic neu-
rons. Therefore we suggest that the imbalance between
neuron populations in EPM2A-/- mice disturb the
cortical network resulting in the pathogenesis of Lafora
disease.
Further more, we described that of synaptophysin and
synaptotagmin expression at early ages (since P5) is
downregulated in the cerebral cortex of EPM2A-/- mice,
indicating a reduction in the number of synapse. This
evidence could suggest an important new role for
laforin in the formation or the maintenance of synapses,
which is worth to be more deeply investigated, in order
to be confirmed.
The EPM2A-/- mice brain also show the proliferation
of enlarged lysosomes, lipofuscin granules, β-amyloid
peptides and increased levels of insoluble form of ubi-
quitinated protein, indicating a significant impairment in
the cellular degradation pathway [35,36]. Moreover, ab-
normal dendrites and increased gliosis, especially in
proximity of LBs, were noted in Lafora disease brain
(Additional file 3: Figure S3). It is well described that in
other neurodegenerative diseases, such as Alzheimer’s
disease, neurotoxic peptides induce the activation of
lysosomal pathways and the increase of the lysosomal
marker LAMP2 levels [37]. LAMP2 acts as a receptor
for a selective pathway of degradation of cytosolic pro-
teins in lysosomes known as chaperone-mediated au-
tophagy. In this pathway, specific cytosolic proteins aredirectly transported through the lysosomal membrane into
the lysosomal matrix where they are degraded. Recently, it
was suggested that some of the neuropathological changes
in Lafora are likely to be side effects caused of the presence
of LBs [36]. Moreover, it was demonstrated that impair-
ment in the autophagy-endosomal-lysosomal pathways
might underlie some of the symptoms in Lafora disease
[36,38]. Analyzing the expression of LAMP2, we demon-
strated that lysosomal activity and autophagy are increased
at different ages in the cerebral cortex of EPM2A-/- mice,
corroborating the results published by Puri et al, 2012 [36].
In addition, we highlight the presence of actin disar-
rangement in cortical neurons of EPM2A-/- mice, which
resembles the characteristics of other neurodegenerative
disease, such as Alzheimer’s disease, where actin de-
posits have been found in the hippocampus and the
cerebral cortex of post-mortem brains, predominantly
localized in amyloid containing neurites [39]. The origin
and role of these inclusions in Lafora disease are un-
known, however, this data do arise the possibility that
LBs contribute to the actin disarrangement and could be
involved in the loss of synapses.
Current clinical and neuropathological views consider
LBs to be the cause of neurological derangement of pa-
tients, however the defining characteristics of apoptosis
in neurons were not found in EPM2A-/- mice. During
the last year, Machado-Salas et al. described the presence
of necrotic neuronal death in the hindbrain, in absence
of LBs, in young EPM2A-/- mice (P11) [33,40]. They
demonstrated that both cell death and LBs showed a in-
crease progressively with age.
In the present article, we show an increase of active-
caspase-3 in the cerebral cortex of 1 month-old mice,
which surprisingly appears specifically in the glutamatergic
neurons of the cerebral cortex. We could not detect any
GABAergic neuron with active-caspase-3 or TUNEL-
positive staining at any of the three ages, suggesting that
the decrease of GABAergic neurons population is not due
to specific cell death, but it is rather probable that the lack
of laforin induces an impaired GABAergic neurodevelop-
ment in the cerebral cortex.
In order to evaluate the effects of the lack of laforin in
the development of the cerebral cortex of EPM2A-/- mice,
we detected the content of p53 in subcellular fractions of
cortical neurons from P15 and P30 mice. The tumour sup-
pressor gene p53 plays a central role in the maintenance
of genomic stability [41,42]. Versatility in p53 activity, as a
response to various external or internal signals, may serve
as a control mechanism, which underlies central decisions
in developmental pathways in vivo [43]. Furthermore, a
number of studies indicate the involvement of p53 in de-
velopmental pathways of neural cells. Differentiation of rat
primary cultures of neurons in culture was shown to be
accompanied by the migration of p53 protein into the
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p53 seems to play an important role in the activity of the
p53 molecule. Both, import into the nucleus and export to
the cytoplasm, appear to be mediated by specific pathways
that are associated with either the stabilization of the ac-
tive protein or its inactivation by degradation, respectively.
p53 was detected in the nuclear fraction of P15 and P30
mice, while little signal was detected in the cytoplasmic
fraction. Although more experiments are necessary, these
preliminary results suggested that laforin is related to the
regulation of p53 subcellular localization.
It is beyond doubt that the neurotrophin family of pro-
teins plays key roles in determining the fate of the neuron,
not only during embryonic development, but also in the
adult brain [45]. Neurotrophins such as NGF (nerve growth
factor) and BDNF (brain-derived neurotrophic factor) can
play dual roles: first, in neuronal survival and death, and,
secondly, in activity-dependent plasticity. BDNF is abun-
dantly expressed in the brain and plays a crucial role in
activity-dependent plastic changes in synaptic strength and
network refinement [46,47]. BDNF has been implicated in
regulating adult neurogenesis in the subventricular zone
of the dentate gyrus and also in the development of the
GABAergic interneurons [48,49]. BDNF also has been
described in the epilepsy [50,51]. The implications of
neurotrophins in the development of Lafora disease are
unknown. We hypothesize that, since Lafora disease is a
type of epilepsy with GABA neurons impairment, it is
possible that neurotrophins may be involved in disease
development. The neurotrophins manifest their effects
by binding to two discrete receptor subtypes: the Trk
(tropomyosin receptor kinase) family of RTKs (receptor
tyrosine kinases) and the receptor p75NTR [26]. The al-
tered metabolism of NGF and BDNF could be induced
or aggravated by the neurodegeneration in the brain pa-
tients with Lafora disease. To characterize the NGF and
BDNF expression in cerebral cortex from EPM2A-/-
mice, we evaluated analysis of NGF, BDNF and the re-
ceptor implicated in the apoptosis of neurons, the
p75NTR in cerebral cortex lysates from 15 days-old and
1 month-old of age. At both ages NGF and BDNF levels
decreased and p75NTR increased. The receptor
p75NTR is known to be involved in signalling apoptosis
in a number of cell models by NGF binding [52,53]. The
increase of p75NTR in Alzheimer’s disease affected hu-
man brain is not fully accepted in the literature, none-
theless the increase of p75NTR processing, which tends
to translocate to the nucleus, was described in this neu-
rodegenerative disease [54]. We described for the first
time the pathophysiological role of p75NTR in Lafora dis-
ease; we showed an increase in the ICD-p75NTR levels.
Whether the ICD-p75NTR is directed to the nucleus has
been very difficult to determine due to the instability and
the extremely low levels of the ICD fragment [55].Notwithstanding, in our study it remains to be established
whether the ICD-p75NTR generated is directed to the nu-
cleus of these neurons. Our data revealed a surprising re-
sult in laforin deficient mice, since we were not able to
detect nuclear translocation of ICD-p75NTR fragment.
Intramembrane cleavage events have been detected not
only for p75NTR in many cell types [56]. Proteolysis
through presenilin-dependent γ-secretase activity has
emerged as a highly conserved and prevalent mechanism
in receptor signalling responsible for the intramembrane
cleavage of important proteins, such as Notch, ErbB4 tyro-
sine kinase receptors, CD44, low density lipoprotein, and
β-amyloid precursor protein [57]. To test whether this in-
hibition of nuclear translocation of ICD-p75 in the cere-
bral cortex of Laforin-deficient mice is specific or
presenilin-dependent, we assessed also the ICD levels of
Notch, confirming that in EPM2A-/- mice ICD-Notch did
not translocate to the nucleus. This experiment uphold
that in Lafora disease there is a signalling alteration in the
proteolysis through presenilin-dependent γ-secretase ac-
tivity and this process occurrs at the age of 15 days-old,
before the development of the first LBs.
Up to date, no information regarding p75NTR process-
ing or nuclear translocation of ICD-p75 in apoptosis is
available. Several years ago, a first physiological role was
detected for ICD-p75 yield under myelin-associated
glycoprotein activation in cerebellar neurons, where the
down-regulation of TACE by RNA interference blocked
BDNF-induced p75NTR cleavage and apoptosis [25,54].
However, our results suggest that impairment of
p75NTR signalling and altered neurotrophins levels
(NGF and BDNF) could be involved in the neurodegen-
erative processes of Lafora disease in the cerebral cortex.
Our data prompt that p75NTR may employ regulated
intramembrane proteolysis to transmit an intracellular sig-
nal. Similar to the cleavage of Notch, the ICD-p75NTR
may function as a nuclear transcriptional modulator, acti-
vating/deactivating a set of genes that are involved in cell
death or neuronal differentiation. The relationship be-
tween this process and the induction of neuronal apop-
tosis is still not completely understood, nevertheless these
changes in the neurotrophin signalling occurred before
the appearance of the first LBs. Polyglucosan bodies are
known to be produced normally in neuronal cell and
cleared via axons into cerebrospinal fluid [58]. A physio-
logical role described for ICD-p75NTR was under myelin-
associated glycoprotein activation in cortical neurons for
activation of Rho and inhibition or neurite outgrowth [59].
These results come up with laforin and p75NTR signalling
could be involved in the intercellular and intracellular mi-
gration of polyglucosan, and its loss of function would re-
sult in polyglucosan accumulation as LBs.
Lafora disease has been previously associated altered pro-
tein clearance [60,61]. We believe it is crucial to analyze the
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proteolysis, in the cerebral cortex in EPM2A-/- mice, prior
to the appearance of the first LBs. Our findings showed that
there was a significant decrease in the proteins implicated
in neuroprotection and neurorepair: transthyrretin (TTR),
Clusterin (ApoJ), BDNF, NGF, VEGF; and there was a sig-
nificant increase in proteins implicated with neuropatho-
logical situations: β-Amyloid 1-40 and 1-42 and MMP9. It
was previously published that the level of the Ser9-phospho
(inactive) form of GSK3β was lower in the 10 month-old
EPM2A-/- mice compared to controls, suggesting that
laforin probably acts upstream of this key enzyme [35].
AKT, PKA, and PP1 are a few of the known regulators of
the Ser9 residue of GSK3β [62,63], however, none of the
three showed a significant change in its phosphorylation
pattern, as analyzed by immunoblot of neuronal lysates
from EPM2A-/- mice with 10 month-old.
Conclusions
Our results suggest that Lafora disease is mainly a neuro-
degenerative disease, since neurodevelopment impairment
develops specifically in the cerebral cortex prior to LBs
formation. It is likely therefore that LBs and neurological
damage are independent consequences of the same defect
in a common physiological pathway and it is possible that
only some Lafora disease symptoms are a consequence of
LBs formation. Because Lafora disease has been tradition-
ally classified as a glycogen metabolism disorder, only a
few reports described the neurodegenerative changes in
the neuropile [3,11,64-66]. Nevertheless, our data strongly
support the idea that Lafora disease is both a complex
neurodegenerative disease and a glycogen metabolism
disorder.
The basis that we set up through our findings, are critical
for future studies on the pathology in the cerebral cortex
and hippocampus, as well as for the development of new
therapies for Lafora disease. Interestingly, the neurodegen-
erative changes observed in this Lafora disease model can
also be useful for understanding the neurotrophin signalling
in the process of dementia.
Methods
Animals
Brain tissues of laforin-deficient mice (EPM2A-/- mice)
and their wild-type littermates [12] obtained in frozen
condition and fixed in paraformaldehide from Dr. Santiago
Rodríguez de Cordoba (The Centro de Investigaciones
Biológicas, Spanish National research Council, CSIC,
Madrid, Spain) were homogenized and processed for im-
munoblotting as reported earlier. Cerebral cortex from
wild-type and EPM2A-/- mice of the same age (15 days-
old, 1 month-old, 3 months-old and 13 months-old) were
isolated in ice-cold lysis buffer and processed following
different protocols for total lysates and subcellularfractioning [27]. We analysed samples by immunofluor-
escence coupled to confocal microscopy and immuno-
blot assays. All animals were handled and cared for in
accordance with European Community Council Direct-
ive (86/609/EEC).
Animal ethics statement
All of the experiments were performed according to eth-
ical regulations on the use and welfare of experimental an-
imals of the European Union and the Spanish Ministry of
Agriculture, and the procedures were approved by the bio-
ethical committee of the University Hospital of Vigo.
Immunoassays
For Western blot analysis brain tissue samples were lysed
in PIK buffer (150 mM NaCl, 20 mM TrisHCl pH 7.4, 1%
(v/v) NP40 and protease inhibitors: 1 μg/mL aprotinin,
1 μg/mL leupeptin and 1 μg/mL phenylmethylsulfonyl
fluoride, PMSF). For cell fractionation cells were lysed
with C buffer (10 mM HEPES, 60 mM KCl, 1 mM EDTA,
0.075% (v/v) Triton X100, 1 mM DTT with protease in-
hibitors). The pellet nuclei was obtained by centrifugation
325 g, 4 minutes and resuspended in NB buffer (20 mM
TrisHCl pH 8, 420 mM NaCl, 15 mM MgCl2, 0.2 mM
EDTA, 25% (v/v) Glicerol and protease inhibitors). There-
after, the nuclei supernatant were obtained after centrifu-
gation 9000 g, 10 minutes [67]. To separate the soluble
and insoluble fractions, the brain was lysed and homoge-
nized in PBS, and centrifuged at 10.000 g. After running
the samples in acrylamide gels, proteins were transferred
(immobilon, Bio-Rad) and membranes were incubated
with the corresponding primary antibodies at 4°C over-
night. Afterwards, membranes were washed and incubated
with secondary antibodies. Membranes were washed sev-
eral times with Tween-TBS and developed with ECL plus
(Amersham). Western blot membranes were re-blotted
with unrelated proteins (actin and βIII-Tubulin)) as an in-
ternal standard and normalized for protein load. Densito-
metric analysis was performed using ImageJ software
(NIH Image). A representative blot is shown from a total
of at lest three independent experiments.
Immunofluorescence
The brain was immersion fixed in paraformaldehide 4%
(w/v) in PBS 0.1 M (NaH2PO4 *H2O (13.8 g/L), Na2HPO4
(14.2 g/L), NaCl (8 g/L), pH 7.4) for 24 h, paraffin embed-
ded sections. Sections (10 μm thick) of the brain were
then cut using a microtome (Leica Microsystems, UK).
Brain sections were blocked with 5% (w/v) BSA and incu-
bated overnight at 4°C with the respective antibody in PB
containing 0.5% (w/v) BSA and 0.1 (v/v) Triton X100.
After several washes in PB, sections were incubated with
Alexa-coupled secondary antibody in the same PB buffer.
Emission of primary antibody was used as control. Confocal
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immunohistochemical analysis, preparations were visualized
by light microscopy using DAB conjugated avidin-biotin
complex kit (Vectastain ABC Elite, Vector Laboratories,
USA). For periodic acid-Schiff (PAS)-Diastase staining, sec-
tions were incubated with diastase prior to staining with
PAS reagent for detection of Lafora bodies.
Fluorescence microscopy analysis of Rhodamine
Phalloidin-stained cerebral cortex
Slices were washed twice with phosphate-buffered saline,
fixed in 4% (w/v) paraformaldehyde solution for 10 min at
room temperature, permeated with 0.1% (v/v) Triton X-
100, and stained with rhodamine-phalloidin. Fluorescent
images were monitored using a confocal microscopy lo-
cated in the “Centro de Apoio Científico-Tecnolóxico a
Investigación, CACTI, University of Vigo”.
Quantification of cell death by TUNEL staining
Apoptotic cells were detected using an apoptosis in situ
cell death detection kit (Roche). Analysis of apoptotic
cells was based on the TUNEL procedure, which con-
sists of the addition of apoptotically fragmented DNA to
the 3′ termini by terminal deoxynucleotidyl transferase
followed by immunochemical detection using an anti-
fluorescein antibody conjugated with horseradish perox-
idase and diaminobenzidine as a substrate.Antibodies
The following antibodies were used: rabbit polyclonal
anti-p75NTR against extracellular domain (9651) and
intracellular region (9992) gifted from Dr. M. Chao and
Dr. B. Carter [68]. Mouse monoclonal anti-α-actin (Sigma),
mouse monoclonal anti-βIII-Tubulin (Millipore), anti-
polyglucosans (Kamiya Biomedical Company, USA),
polyclonal anti-GAD67 (Abcam), Mouse monoclonal
anti-synaptophysin (Chemicon), Mouse monoclonal
anti-synaptotagmin (Sigma), mouse monoclonal anti-β-
amyloid (MBL), mouse monoclonal anti-caspase-3 and
rabbit anti-caspase-3-active (Cell Signalling), mouse
monoclonal anti-caspase-9-active (Cell Signalling),
mouse monoclonal anti-p53 (Dako), mouse-monoclonal
anti-NeuN (Millipore), Mouse monoclonal anti-LAMP2
(Abcam), polyclonal anti-LC3 (Cell Signalling), poly-
clonal anti-NGF (Chemicon), polyclonal anti-BDNF
(Abcam), goat-polyclonal anti-Notch (Santa Cruz Biotech-
nologies), rabbit polyclonal anti-Transtyrretin (Santa Cruz
Biotechnologies), polyclonal anti-Apolipoprotein J (Abcam),
polyclonal anti-VEGF (Santa Cruz Biotechnologies), poly-
clonal anti-MMP9 (Santa Cruz Biotechnologies), rabbit
polyclonal anti-phospho Akt (Cell Signalling), rabbit poly-
clonal anti-phospho JNK (Cell Signalling), rabbit polyclonal
anti-Akt (Cell Signalling), mouse monoclonal anti-AT8(Termo Scientific), phalloidin-Rhodamin (Invitrogen). All
Alexa-fluor antibodies were purchased from Invitrogen.
Cell counting
Stereological cell counts and measurements were carried
out using microscope with digital camera and software for
morphometry (Leica AMD). GAD67 neurons cell number
in the cerebral cortex was estimated using standard
model-based stereological methods [69]. Briefly, for neur-
onal counts, brains were blocked and serially-sectioned at
10 μm from the frontal brain to the cerebellar-midbrain
junction. Serial sections were mounted 5 sections per slide
onto polyionic slides. GAD67-positive neurons were
counted using a 40× objective (total magnification 400×).
Specifically, neurons from both left and right sides of the
cerebral cortex within one section per slide (chosen ran-
domly and then maintained throughout all sections were
counted). A neuron was considered to be immunopositive
if it was labelled by the typical brown colour of the DAB
peroxidase reaction product in the cytoplasm and prox-
imal dendrites (see Additional file 1: Figure S1A).Additional files
Additional file 1: Figure S1. The pathological hallmark of Lafora
disease is the presence of cytoplasmic LBs in neurons. The LBs are
indicated with arrows in the picture. A) Immunostaining with the
neuronal marker βIII-Tubulin in temporal and frontal cortex sections of
EPM2A-/- mice at different ages: 3 and 13 months-old (upper pictures)
and combined with PAS staining for specific detection of the LBs
(bottom pictures). B) Confocal images of sections of cerebral cortex
stained with cortical neurons marker GAD67 (green) and LBs detected
with specific polyglucosan antibody (red).
Additional file 2: Figure S2. Detailed analysis of LBs located in the
cytoplasm and dendrites. A) Stereological cytoplasm LBs and ground-
glass inclusions (LBs located in dendrites) counted and measured with
microscope with digital camera and software for morphometry in
EPM2A-/- mice at 5 months-old (n = 3). Although the LBs and ground-
glass inclusions appear in all brain regions, at early ages the highest dens-
ity was placed in cerebral cortex and hippocampus, with lesser amounts
in the basal forebrain and sparse distribution through out the rest of the
brain. B) Cytoplasm LBs emerged at 3 months of age and LBs in dendrites
appeared around 15 days of age. This schematic representation suggests
that the temporary window where the molecular changes occur before
the first LBs are located in the neurons is around 1moth-old.
Additional file 3: Figure S3. Reactive gliosis in the brain temporal
cortex (3 month-old) in EPM2A-/- mice in paraffin blocks (see Methods)
and developed with DAB. A) GFAP immunostaining (left) and PAS
staining (right) of the same cortical area in Laforin-deficient mice. B)
Broad image of GFAP immunostaining combined with PAS staining of
cerebral cortex at EPM2A-/- mice.Abbreviations
CTF: Carboxyl terminal fragment; ICD: Intracellular domain; GABA: Gamma
aminobutyric acic; LB: Lafora body; MMP: Metalloproteinase; RTKs: Receptor
tyrosine kinases.Competing interests
None of the authors of this manuscript have any financial interest that has
influenced the results or interpretation of this manuscript.
Ortolano et al. Molecular Brain 2014, 7:7 Page 16 of 17
http://www.molecularbrain.com/content/7/1/7Authors’ contributions
The work presented here was carried out in collaboration between all
authors. SO and CS defined the research theme, CS, IV and RCAB elaborated
the animal processing and experiments. SO and CS analyzed the data and
interpreted the results. CS and SO wrote the paper. All authors have
contributed to see and approve the manuscript.
Acknowledgements
We thank Santiago Rodriguez de Córdoba for EPM2A -/- mice, and Olga Souto
and Olga Criado for technical assistance. We also thank Bruce Carter (Vanderbilt
University Medical Center, Nashville, TN) and Moses Chao (Skirball Institute, New
York, NY) for p75-ICD and p75-ECD antibodies. Funding from the European Union
Seventh Framework Programme [FP7/REGPOT-2012-2013.1] under grant
agreement n° 316265, BIOCAPS. This work was also supported by grants from
Xunta de Galicia (INCITE2009, 09CSA051905PR), Instituto Carlos Carlos III, Accion
Estratégica en Salud (PI11/00842) and “Isidro Parga Pondal” programme of the
Xunta de Galicia through European Social Fund.
Author details
1Group of Rare Diseases, Institute of Biomedical Research of Vigo (IBIV),
Xerencia de Xestion Integrada de Vigo, SERGAS, Psychiatric Hospital
Rebullón, Puxeiros s/n, Pontevedra 36415 Mos, Spain. 2Group of
Neurodegenerative Diseases and Psychiatric Disorders, Institute of Biomedical
Research of Vigo (IBIV), Xerencia de Xestion Integrada de Vigo, SERGAS,
Psychiatric Hospital Rebullón, Puxeiros s/n, Pontevedra 36415 Mos, Spain.
Received: 6 November 2013 Accepted: 23 January 2014
Published: 28 January 2014
References
1. Chan EM, Andrade DM, Franceschetti S, Minassian B: Progressive
myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv Neurol 2005, 95:47–57.
2. Ganesh S, Puri R, Singh S, Mittal S, Dubey D: Recent advances in the
molecular basis of Lafora’s progressive myoclonus epilepsy. J Hum Genet
2006, 51:1–8.
3. Spuch C, Ortolano S, Navarro C: Lafora progressive myoclonus epilepsy:
recent insights into cell degeneration. Recent Pat Endocr Metab Drug
Discov 2012, 6:99–107.
4. Yokoi S, Austin J, Witmer F, Sakai M: Studies in myoclonus epilepsy (Lafora
body form). Isolation and preliminary characterization of Lafora bodies
in two cases. Arch Neurol 1968, 19:15–33.
5. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I,
Gardner R, Fong CY, Carpenter S, Jardim L, Satishchandra P, Andermann E, Snead
OC 3rd, Lopes-Cendes I, Tsui LC, Delgado-Escueta AV, Rouleau GA, Scherer SW:
Mutations in a gene encoding a novel protein tyrosine phosphatase cause
progressive myoclonus epilepsy. Nat Genet 1998, 20:171–174.
6. Serratosa JM, Gómez-Garre P, Gallardo ME, Anta B, de Bernabé DB, Lindhout D,
Augustijn PB, Tassinari CA, Malafosse RM, Topcu M, Grid D, Dravet C, Berkovic SF,
de Córdoba SR: A novel protein tyrosine phosphatase gene is mutated in
progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet
1999, 8:345–352.
7. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G,
Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-
Escueta AV, Minassian BA, Scherer SW: Mutations in NHLRC1 cause progressive
myoclonus epilepsy. Nat Genet 2003, 35:125–127.
8. Chan EM, Bulman DE, Paterson AD, Turnbull J, Andermann E, Andermann F,
Rouleau GA, Delgado-Escueta AV, Scherer SW, Minassian BA: Genetic
mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B)
on 6p22. J Med Genet 2003, 40:671–675.
9. Chan EM, Omer S, Ahmed M, Bridges LR, Bennett C, Scherer SW, Minassian
BA: Progressive myoclonus epilepsy with polyglucosans (Lafora disease):
evidence for a third locus. Neurology 2004, 63:565–567.
10. Turnbull J, Girard JM, Lohi H, Chan EM, Wang P, Tiberia E, Omer S, Ahmed
M, Bennett C, Chakrabarty A, Tyagi A, Liu Y, Pencea N, Zhao X, Scherer SW,
Ackerley CA, Minassian BA: Early-onset Lafora body disease. Brain 2012,
135:2684–2698.
11. Valles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L,
Serafin A, Cañas X, Soriano E, Delgado-García JM, Gruart A, Guinovart JJ:
Neurodegeneration and functional impairments associated with
glycogen synthase accumulation in a mouse model of Lafora disease.
EMBO Mol Med 2011, 3:667–681.12. Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y,
Akagi T, Gomi H, Suzuki T, Amano K, Agarwala KL, Hasegawa Y, Bai DS, Ishihara
T, Hashikawa T, Itohara S, Cornford EM, Niki H, Yamakawa K: Targeted disruption
of the Epm2a gene causes formation of lafora inclusion bodies, neurodegen-
eration, ataxia, myoclonus epilepsy and impaired behavioral response in
mice. Hum Mol Genet 2002, 11:1251–1262.
13. Gentry MS, Romá-Mateo C, Sanz P: Laforin, a protein with many faces:
glucan phosphatase, adapter protein et alii. FEBS J 2013, 280:525–537.
14. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, Delgado-
Escueta AV, Minassian BA, Depaoli-Roach AA, Roach PJ: Laforin is a glyco-
gen phosphatase, deficiency of which leads to elevated phosphorylation
of glycogen in vivo. Proc Natl Acad Sci USA 2007, 104:19262–19266.
15. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, Minassian BA,
Depaoli-Roach AA, Roach PJ: Abnormal metabolism of glycogen phosphate as
a cause for Lafora disease. J Biol Chem 2008, 283:33816–33825.
16. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS: Glycogen and its
metabolism: some new developments and old themes. Biochem J 2012,
441:763–787.
17. Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, Ackerley CA,
Minassian BA: Novel glycogen synthase kinase 3 and ubiquitination
pathways in progressive myoclonus epilepsy. Hum Mol Genet 2005,
14:2727–2736.
18. Solaz-Fuster MC, Gimeno-Alcañiz JV, Ros S, Fernandez-Sanchez ME, Garcia-
Fojeda B, Criado Garcia O, Vilchez D, Dominguez J, Garcia-Rocha M,
Sanchez-Piris M, Aguado C, Knecht E, Serratosa J, Guinovart JJ, Sanz P, Rodri-
guez de Córdoba S: Regulation of glycogen synthesis by the laforin-malin
complex is modulated by the AMP-activated protein kinase pathway.
Hum Mol Genet 2008, 17:667–678.
19. Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, Scherer
SW, Minassian BA: Laforin preferentially binds the neurotoxic starch-like
polyglucosans, which form in its absence in progressive myoclonus epi-
lepsy. Hum Mol Genet 2004, 13:1117–1129.
20. Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S,
San Millán B, Heredia M, Romá-Mateo C, Mouron S, Juana-López L, Domín-
guez M, Navarro C, Serratosa JM, Sanchez M, Sanz P, Bovolenta P, Knecht E,
Rodriguez de Cordoba S: Lafora bodies and neurological defects in malin-
deficient mice correlate with impaired autophagy. Hum Mol Genet 2012,
21:1521–1533.
21. Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Pili-
guian M, Roach PJ, Wang P, Ackerley CA, Minassian BA: PTG depletion
removes lafora bodies and rescues the fatal epilepsy of lafora disease.
PLoS Genet 2011, 7:e1002037.
22. Monaghan TS, Delanty N: Lafora disease: epidemiology, pathophysiology
and management. CNS Drugs 2010, 24:549–561.
23. Martin DL, Barke KE: Are GAD65 and GAD67 associated with specific
pools of GABA in brain? Perspect Dev Neurobiol 1998, 5:119–129.
24. Zampieri N, Xu CF, Neubert TA, Chao MV: Cleavage of p75 neurotrophin
receptor by α-secretase and γ-secretase requires specific receptor
domains. J Biol Chem 2005, 280:14563–14571.
25. Domeniconi M, Zampieri N, Spencer T, Hilaire M, Mellado W, Chao MV, Filbin MT:
MAG induces regulated intramembrane proteolysis of the p75 neurotrophin
receptor to inhibit neurite outgrowth. Neuron 2005, 46:849–855.
26. Vilar M, Charalampopoulos I, Kenchappa RS, Reversi A, Klos-Applequist JM,
Karaca E, Simi A, Spuch C, Choi S, Friedman WJ, Ericson J, Schiavo G, Carter BD,
Ibáñez CF: Ligand-independent signaling by disulfide-crosslinked dimers of
the p75 neurotrophin receptor. J Cell Sci 2009, 122:3351–3357.
27. Spuch C, Carro E: The p75 neurotrophin receptor localization in blood-CSF
barrier: expression in choroid plexus epithelium. BMC Neurosci 2011, 12:39.
28. Busard HL, Renier WO, Gabreels FJ, Jaspar HH, Slooff JL, Janssen AJ, Van
Haelst UJ: Lafora disease: a quantitative morphological and biochemical
study of the cerebral cortex. Clin Neuropathol 1987, 6:1–6.
29. Douglas R, Martin K: Neocortex. In The Synaptic Organization of the Brain.
4th edition. Edited by Shepherd GM. Oxford, UK: Oxford University Press;
1998:459–509.
30. Canafoglia L, Ciano C, Panzica F, Scaioli V, Zucca C, Agazzi P, Visani E, Avanzini G,
Franceschetti S: Sensorimotor cortex excitability in Unverricht-Lundborg
disease and Lafora body disease. Neurology 2004, 63:2309–2315.
31. Canafoglia L, Ciano C, Visani E, Anversa P, Panzica F, Viri M, Gennaro E, Zara F,
Madia F, Franceschetti S: Short and long interval cortical inhibition in
patients with Unverricht-Lundborg and Lafora body disease. Epilepsy Res
2010, 89:232–237.
Ortolano et al. Molecular Brain 2014, 7:7 Page 17 of 17
http://www.molecularbrain.com/content/7/1/732. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davis SW:
Nonapoptotic neurodegeneration in a transgenic mouse model of
Huntington’s disease. Proc Natl Acad Sci USA 2000, 97:8093–8097.
33. Machado-Salas J, Avila-Costa MR, Guevara P, Guevara J, Durón RM, Bai D,
Tanaka M, Yamakawa K, Delgado-Escueta AV: Ontogeny of Lafora bodies
and neurocytoskeleton changes in laforin-deficient mice. Exp Neurol 2012,
236:131–140.
34. Tsuda H, Katsumi Y, Nakamura M, Ikeda A, Fukuyama H, Kimura J, Shibasaki H:
Cerebral blood flow and metabolism in Lafora disease. Rinsho Shinkeigaku
1995, 35:175–179.
35. Puri R, Suzuki T, Yamakawa K, Ganesh S: Hyperphosphorylation and
aggregation of Tau in laforin-deficient mice, an animal model for lafora
disease. J Biol Chem 2009, 284:22657–22663.
36. Puri R, Suzuki T, Yamakawa K, Ganesh S: Dysfunctions in endosomal-lysosomal
and autophagy pathways underlie neuropathology in a Mouse model for
Lafora disease. Hum Mol Genet 2012, 21:175–184.
37. Sofroniew MV, Vinters HV: Astrocytes: biology and pathology.
Acta Neuropathol 2010, 119:7–35.
38. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, Sanz P,
de Córdoba SR, Knecht E, Rubinsztein DC: Laforin, the most common
protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet
2010, 19:2867–2876.
39. Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR:
Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that
disrupt distal neurite function. Nat Cell Biol 2000, 2:628–636.
40. Vilchez D, Ros S, Cifuentes D, Pujadas L, Vallès J, García-Fojeda B, Criado-
García O, Fernández-Sánchez E, Medraño-Fernández I, Domínguez J, García-
Rocha M, Soriano E, Rodríguez de Córdoba S, Guinovart JJ: Mechanism
supressing glycogen synthesis in neurons and its demise progressive
myoclobus epilepsy. Nat Neurosci 2007, 10:1407–1413.
41. Gottlieb MT, Oren M: p53 in growth control and neoplasia.
Biochim Biophys Acta 1996, 1287:77–102.
42. Ko JL, Prives C: p53: puzzle and paradigm. Genes Dev 1996, 10:1054–1072.
43. Tendler Y, Weisinger G, Coleman R, Diamond E, Lischinsky S, Kerner H,
Rotter V, Zinder O: Tissue-specific p53 expression in the nervous system.
Brain Res Mol Brain Res 1999, 72:40–46.
44. Eizenberg O, Faber-Elman A, Gotlieb E, Oren M, Rotter V, Schwartz M: Direct
involvement of p53 in programmed cell death of oligodendrocytes.
EMBO J 1995, 14:1136–1144.
45. Schecterson LC, Bothwell M: Neurotrophin receptors: old friends with new
partners. Dev Neurobiol 2010, 70:332–338.
46. Lewin GR, Barde YA: Physiology of neurotrophins. Annu Rev Neurosci 1996,
19:289–317.
47. Lu B, Figurov A: Role of neurotrophins in synapse development and
plasticity. Rev Neurosci 1997, 8:1–12.
48. Alcantara S, Pozas E, Ibañez CF, Soriano E: BDNF-modulated spatial
organization of Cajal-Retzius and GABAergic neurons in the marginal
zone plays a role in the development of cortical organization.
Cereb Cortex 2006, 16:487–499.
49. Waterhouse EG, An JJ, Orefice LL, Baydyuk M, Liao GY, Zheng K, Lu B, Xu B:
BDNF promotes differentiation and maturation of adult-born neurons
through GABAergic transmission. J Neurosci 2012, 32:14318–14330.
50. Binder DK, Croll SD, Gall CM, Scharfman HE: BDNF and epilepsy: too much
of a good thing? Trends Neurosci 2001, 19:47–53.
51. Reibel S, Depaulis A, Larmet Y: BDNF and epilepsy–the bad could turn out
to be good. Trends Neurosci 2001, 24:318–319.
52. Friedman WJ: Neurotrophins induce death of hippocampal neurons via
the p75 receptor. J Neurosci 2000, 20:6340–6346.
53. Naumann T, Casademunt E, Hollerbach E, Hofmann J, Dechant G, Frotscher M,
Barde YA: Complete deletion of the neurotrophin receptor p75NTR leads to
long-lasting increases in the number of basal forebrain cholinergic neurons.
J Neurosci 2002, 22:2409–2418.
54. Kenchappa RS, Tep C, Korade Z, Urra S, Bronfman FC, Yoon SO, Carter BD:
p75 neurotrophin receptor-mediated apoptosis in sympathetic neurons
involves a biphasic activation of JNK and up-regulation of tumor
necrosis factor alpha converting enzyme/ADAM17. J Biol Chem 2010,
285:20358–20368.
55. Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS,
Ryu SH, Chao MV, Kim TW: Regulated intramembrane proteolysis of the
p75 neurotrophin receptor modulates its association with the TrkA
receptor. J Biol Chem 2003, 278:42161–42169.56. Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecterson LC:
Proteolytic processing of the p75 neurotrophin receptor and two
homologues generates C-terminal fragments with signaling capability.
J Neurosci 2003, 23:5425–5436.
57. Ebinu JO, Yankner BA: A RIP tide in neuronal signal transduction.
Neuron 2002, 34:499–502.
58. Cavanagh JB: Corpora-amylacea and the family of polyglucosan diseases.
Brain Res Brain Res Rev 1999, 29:265–295.
59. Perdigoto AL, Chaudhry N, Barnes GN, Filbin MT, Carter BD: A novel role for
PTEN in the inhibition of neurite outgrowth by muelin-associated
glycoprotein in cortical neurons. Mol Cell Neurosci 2011, 46:235–244.
60. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, Roach PJ:
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora
bodies and the accumulation of insoluble laforin. J Biol Chem 2010,
285:25372–25381.
61. Delgado-Escueta AV: Lafora progressive myoclonus epilepsy: glycogen
storage disease vs neurodegenerative disease. Neurology 2012, 79:21–22.
62. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB: Phosphorylation and
inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl
Acad Sci USA 2000, 97:11960–11965.
63. Szatmari E, Habas A, Yang P, Zheng JJ, Hagg T, Hetman M: A positive
feedback loop between glycogen synthase kinase 3beta and protein
phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain
neurons. J Biol Chem 2005, 280:37526–37535.
64. Busard HL, Span JP, Renkawek K, Renier WO, Gabreëls FJ, Slooff JL, Hof MA V’t:
Polyglucosan bodies in brain tissue: a systematic study. Clin Neuropathol
1994, 13:60–63.
65. Gentry MS, Dixon JE, Worby CA: Lafora disease: insights into
neurodegeneration from plant metabolism. Trends Biochem Sci 2009,
34:628–639.
66. Duran J, Tevy MF, Garcia-Rocha M, Calbó J, Milán M, Guinovart JJ: Deleterious
effects of neuronal accumulation of glycogen in flies and mice. EMBO Mol
Med 2012, 4:719–729.
67. Spuch C, Antequera D, Portero A, Orive G, Hernández RM, Molina JA,
Bermejo-Pareja F, Pedraz JL, Carro E: The effect of encapsulated VEGF-
secreting cells on brain amyloid load and behavioral impairment in a
mouse model of Alzheimer’s disease. Biomaterials 2010, 31:5608–5618.
68. Huber LJ, Chao MV: Mesenchymal and neuronal cell expression of the
p75 neurotrophin receptor gene occur by different mechanisms. Dev Biol
1995, 167:227–238.
69. Baquet ZC, Williams D, Brody J, Smeyne RJ: A comparison of model-based
(2D) and design-based (3D) stereological methods for estimating cell
number in the substantia nigra pars compacta (SNpc) of the C57BL/6 J
Mouse. Neuroscience 2009, 161:1082–1090.
doi:10.1186/1756-6606-7-7
Cite this article as: Ortolano et al.: Loss of GABAergic cortical neurons
underlies the neuropathology of Lafora disease. Molecular Brain 2014 7:7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
